Eisai and Biogen have recently reported long-term data on their therapy, Leqembi (lecanemab), which showed that it is able to ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

If you'd like to learn more or get involved, the Dallas Walk to End Alzheimer's starts Saturday morning at 8:30 at Dallas ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

Roughly 82 percent of Americans support requiring Medicare and insurance companies to cover the Alzheimer's treatments.

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...